First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity von Brignone, Chrystelle, Gutierrez, Maya, Mefti, Fawzia, Brain, Etienne, Jarcau, Rosana, Cvitkovic, Frédérique, Bousetta, Nabil, Medioni, Jacques, Gligorov, Joseph, Grygar, Caroline, Marcu, Manon, Triebel, Frédéric

Volltext

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma von BRIGNONE, Chrystelle, ESCUDIER, Bernard, GRYGAR, Caroline, MARCU, Manon, TRIEBEL, Frédéric

Volltext

A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells von Brignone, Chrystelle, Grygar, Caroline, Marcu, Manon, Schakel, Knut, Triebel, Frederic

Volltext

IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: A single-blind phase I study von Brignone, Chrystelle, Grygar, Caroline, Marcu, Manon, Perrin, Gaëlle, Triebel, Frédéric

Volltext

IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study von Brignone, Chrystelle, Grygar, Caroline, Marcu, Manon, Perrin, Gaëlle, Triebel, Frédéric

Volltext

Shaping the future of male reproductive health: fostering talent at the 14th Network of Young Researchers in Andrology meeting von Marcu, Daniel, Egeberg, Dorte, Richer, Guillaume, Oud, Manon, Houston, Brendan, Berres, Sven, de la Iglesia, Alberto

Volltext